Abstract
Coronary atherosclerosis, the main condition predisposing to acute myocardial infarction, has an inflammatory component caused by stimuli that are yet unknown. We molecularly investigated the nature of the immune response within human coronary lesion in four coronary plaques obtained by endoluminal atherectomy from four patients. We constructed phage-display libraries containing the IgG1/kappa antibody fragments produced by B-lymphocytes present in each plaque. By immunoaffinity, we selected from these libraries a monoclonal antibody, arbitrarily named Fab7816, able to react both with coronary and carotid atherosclerotic tissue samples. We also demonstrated by confocal microscopy that this monoclonal antibody recognized human transgelin type 1, a cytoskeleton protein involved in atherogenesis, and that it co-localized with fibrocyte-like cells transgelin+, CD68+, CD45+ in human sections of coronary and carotid plaques. In vitro fibrocytes obtained by differentiating CD14+ cells isolated from peripheral blood mononuclear cells also interacted with Fab7816, thus supporting the hypothesis of a specific recognition of fibrocytes into the atherosclerotic lesions. Interestingly, the same antibody, cross-reacted with the outer membrane proteins of Proteus mirabilis and Klebsiella pneumoniae (and possibly with homologous proteins of other enterobacteriaceae present in the microbiota). From all the other three libraries, we were able to clone, by immunoaffinity selection, human monoclonal antibodies cross-reacting with bacterial outer membrane proteins and with transgelin. These findings demonstrated that in human atherosclerotic plaques a local cross-reactive immune response takes place.
Introduction
Atherosclerosis is a slowly progressing disease with an inflammatory component in which the adaptive immunity is directly involved since its early stages down to the progression and acute degeneration of advanced lesions [1]–[2]. Targeted biological treatment for coronary and carotid atherosclerotic diseases is still limited and this is mainly due to their complex pathogenesis being still far from being fully understood. B cells have already been described both in animal models and in human atherosclerotic lesions, where they can display an organization resembling tertiary lymphoid organs [3], [4], [5] which sustain a chronic proinflammatory environment [6]. We have recently documented an oligoclonal distribution of B cells in atherosclerotic plaques with the molecular evidence of an antigen-driven B cell maturation within human coronary lesions [7]. Interestingly, in patients with acute coronary syndrome (ACS), an oligoclonal population of T cells in unstable coronary plaques was also described, further suggesting the persistence of local targets of the immune response [8]. Previous demonstration in the coronary plaque of a local B-cell and T-cell response suggested that exogenous agents including bacteria and viruses may play a causal role in the local inflammation [9]. Incompletely understood microbes-host interactions have been associated with the initiation, perpetuation and re-exacerbation of atherosclerotic lesions eventually leading to thrombus formation and acute coronary syndromes or stroke [10], [11], [12], [13], [14], [15]. Recent studies showed that atheromas collect bacteria from the circulation and microbial molecular signatures have been detected in progressively higher frequency in advanced lesions [16], [17]. Nevertheless, even if many observations suggest an involvement of several microbes in the pathogenesis of atherosclerosis, definitive exogenous players have not been clearly identified yet [11], [12], [18], [19]. In parallel, endogenous triggers (such as oxLDL) may play a role in the pathogenesis of coronary plaques, in analogy with the chronic inflammatory processes observed in autoimmune diseases [9], [20], [21], [22].
We now demonstrate, by molecular cloning in a phage display library of the IgG1/k repertoire present in coronary plaques and subsequent generation of human monoclonal antibodies, that B cells in the plaques of four different ACS patients produce antibody clones cross-reacting with the OMPs of gram- bacteria (K. pneumoniae and P mirabilis) and with transgelin (TAGLN), a cytoskeleton protein present in adult human smooth muscle cells (SMC) and other cell types (Figure 1) [23]. We also demonstrate that these antibodies recognized TAGLN expressed in cells with the phenotypic features of fibrocytes, a monocyte-derived-cell population present in coronary and carotid plaque sections. These cells are plastic monocyte-derived cells that migrate and differentiate under chronic inflammatory stimuli as previously observed in several autoimmune conditions such as scleroderma, autoimmune thyroiditis and rheumatoid arthritis [24]. The identification of local and exogenous antigenic stimuli recognized by the local adaptive immune response in human lesions explains the reason for the active recruitment of B cells in human lesions and has the potential of opening new vistas in the understanding of their role in the pathogenesis of acute coronary disease and to plan novel strategy in order to modulate the inflammatory component of the atherosclerotic process.
Results
Combinatorial Libraries Construction and Selection of Fab7816 from Biopanning with Library ID-A on Atherosclerotic Carotid Lysates
Four combinatorial antibody Fab fragment phage-display libraries were generated from four coronary plaques (ID-A, ID-B, ID-C and ID-D). Clinical characteristics of the four patients from which the plaques were obtained were recorded and shown in table S1. In particular, each patient was showing an heterogeneous combination of known risk factors for cardiovascular events such as family history, hypertension, smoking and high cholesterol levels and the analyzed plaques were causing an average 67.75% coronary lumen reduction. Three patients entered the coronary unit with the clinical manifestation of an infarction and another one with the diagnosis of unstable angina.
After generation of combinatorial phage-display libraries, sequencing was performed on a sample of clones and results of heavy and light chains analyses are shown in table S2. Results from the preliminary screening performed on all the libraries were compatible with the oligoclonality previously observed in coronary samples and with a limited number of clones with different junctions (meaning distinct B-cell receptors) [7]. Size of all libraries guaranteed all possible heavy and light chain combinations present in each phage display library. Apparently no preferential V gene usage was observed and all heavy and light chain genes were highly mutated, as determined by comparison with germline sequences (table S2). Library ID-A showed the highest number of clones with different junctions both in the light and in the heavy chains at sequence screening and was thus chosen for immunoaffinity selection against atherosclerotic carotid plaque lysates.
After four rounds of biopanning, the procedure was stopped, the eluted phages recovered and the phage-displayed Fabs were solubilised in order to confirm atherosclerotic carotid plaque lysates binding. Thirty individually selected Fab preparations were screened in ELISA on carotid lysates and each phagemidic vector was sequenced (Figure 2). The majority of clones were bearing an identical combination of heavy and light chain genes (with the IGHV4-61 and IGKV4-1 minigenes respectively) coding for a Fab that we named Fab7816 (Figure 2). Fab 7816 was purified, then used for identification of the antigens recognized in the carotid lysate.
Fab7816 Recognizes TAGLN as Putative Natural Self-antigen in Atherosclerotic Lesions
The protein present in human atherosclerotic carotid preparations that was recognized by Fab7816 was identified by Bidimensional electrophoresis (2DE) of carotid plaque lysates (Figure 3) and by mass spectrometry analysis on proteins sampled from two distinct spots in the 2D gel. These experiment unequivocally identified TAGLN as the putative antigen recognized by Fab7816 with almost complete protein coverage of TAGLN in mass spectrometry analysis. 2D gel showed that possibly more than one TAGLN isoforms, with different Ip, were recognized by Fab7816. In fact in both spots of the 2D gel, TAGLN was recognized by Fab7816 (Figure 3B).
Fab7816-FLAG Stains a Cell Subset with the Phenotypic Features of Fibrocytes in Atherosclerotic Coronary and Carotid Tissues Samples and Recognize Human Fibrocytes in vitro
Confocal microscopy analysis on human coronary plaque sections showed specific interaction of Fab7816-FLAG with cellular antigens present in the tissue from its originary coronary plaque (plaque ID-A) (Figure 4a), as well as with cells localized under the fibrous cap into a carotid plaques (Figure 4b). Anti Hepatitis C virus human monoclonal E8Fab-FLAG [25], used as a negative control, failed to show any specific signal (Figure S1). A subset of TAGLN+/CD45+ cells was recognized by Fab7816-FLAG in human coronary samples (Figure 4a). To further characterize the binding capability of Fab7816-FLAG to atherosclerotic tissue antigens, carotid plaque samples were used (Figure 4b, 5,6 and 7). Specific interaction of Fab7816-FLAG but not of E8Fab-FLAG was observed. Fab7816-FLAG labelled carotid plaque antigens localized in the intima (Figure 4,5,6) in 19 patients out of 31 (table S3), and more rarely in the sub-adventitia (not shown). In our limited series of patients no correlation between the presence of an mmunoreactivity vs. Fab7816-FLAG and the histological features of carotid plaque was found (table S3). Double and multiple staining were performed. Double staining with Fab7816-FLAG and anti- TAGLN antibodies (either monoclonal or polyclonal) demonstrated the existence of Fab7816-FLAG+/TAGLN+, (figures S1, S2, S3 and negative controls figure S4) and of Fab7816-FLAG+/CD68+ cells into the carotid plaque (figure S2). By multiple staining the Fab7816-FLAG+ appeared TAGLN+/CD68+ (Figure 5 and negative samples figure S4), and Coll type I+/CD45+ (Figure 6). Moreover triple labelling showed that Fab7816-FLAG+ cells are TAGLN+/CD45+, thus demonstrating that Fab7816-FLAG recognized in the atherosclerotic lesions a subset of cells of monocytoid origin and with a fibrocyte phenotype. In vitro culture of fibrocytes differentiated from CD14+ circulating monocytes from healthy donors (figure 7a) and displaying the main phenotypic markers (figure S5A,B) demonstrated the presence Fab7816-FLAG specific binding in CD45+ cells (Figure 7b). further confirming the specificity of Fab7816-FLAG for fibrocytes.
Fab7816 Cross-reacts with OmpK36 and OmpF
Purified Fab7816 was also tested for its capability to bind and to identify potentially exogenous antigens by screening bacterial lysates in western blot (WB). Fab7816 recognized a protein band of about 35 kD in Proteus mirabilis and Klebsiella pneumoniae lysates. (Figure 8) Among the proteins of Klebsiella pneumoniae with this molecular weight, we cloned and purified the major outer membrane protein (OmpK36). OmpK36 was expressed in E. coli BL21(DE3) strain (Figure 8A) and Fab7816 staining of induced E. coli BL21(DE3) demonstrated specific binding of Fab7816 to OmpK36. Binding experiments on cloned and purified outer membrane protein F (OmpF) of P.mirabilis confirmed that Fab 7816 is able to recognize also the homologous target in P.mirabilis lysate (OmpF) (Figure 8b).
Antibodies Similar to Fab7816, Recognizing TAGLN and Outer Membrane Proteins (OMPs), are Present in the Locally Produced Antibody Repertoire in Other Three Coronary Plaques from Distinct Patients
To prove that the local production of antibody clones crossreacting with TAGLN and OMPs in atherosclerotic plaque ID-A was not incidental, nor a single lesion-related finding, the biopanning selection was performed with all three additional libraries from three distinct patients on purified OmpK36 (figure 1 and table S2) since Fab7816 reacted poorly on commercial purified TAGLN in ELISA (Figure S6), OmpK36 was preferred for immunoaffinity selection with the other three libraries. After four independent selection rounds with libraries ID-B, ID-C or ID-D on purified OmpK36, biopanning was stopped and 30 single clones for each library where screened in ELISA on purified OmpK36 and sequenced (Figure 9). Several distinct Fabs, bearing different combinations of heavy and light chains, but all able to specifically bind K.pneumoniae OmpK36, were cloned from each library. For each plaque either the most represented among the selected clones or the best reacting Fab at screening was produced and purified. The obtained representative Fabs were named Fab248 (from plaque ID-B), Fab172 (from plaque ID-C) and Fab1630 (from plaque ID-D).
All Representative Fabs Recognised in Purified Human TAGLN and Bacterial OMPs
All representative Fabs displayed a strong binding and cross-reacting capability against both OMPs and human TAGLN (Figure 10). In particular, ELISA and WB experiments, conducted using purified commercial human TAGLN preparations showed that all Fabs bind to TAGLN in WB (FIG. 10a) but not in ELISA (Figure S6) as initially observed with Fab7816 (figure S6). Since electrophoresis was conducted under denaturing conditions, it is very likely that Fabs recognized a linear epitope of the TAGLN protein that is poorly exposed in these ELISA conditions, whilst fully accessible in WB under denaturing conditions (see also Figure 3b). Reactivity was also verified with Fab7816 expressed and purified as full IgG (IgG7816) (protocol S1) (figure 10).
All representative Fabs confirmed their binding both to Proteus mirabilis and Klebsiella pneumoniae purified OMPs in WB (only WB on OmpK36 is shown in Figure 10b) and in ELISA (figure 10c). Reactivity was also verified with Fab7816 expressed and purified as full IgG (IgG7816) (figure 10b and 10c). To confirm that binding followed an antigen-driven affinity maturation and to exclude the superantigenic nature [26] of OMPs binding by our Fabs, the germline (GL) reverted Fab7816 (protocol S2) was tested against the purified bacterial antigens. Purified Fab7816GL did not recognize OMPs (data not shown).
Commercial Monoclonal Antibodies Against Human TAGLN Cross-react with Klebsiella pneumoniae OmpK36 and P.mirabilis OmpF
Five different commercial monoclonal mouse anti-human TAGLN IgG antibodies (Abnova, H00006876-M01, M02, M03, M04, M05) and a monoclonal mouse anti-human TAGLN IgM antibody (Abnova, H00006876-M06A) were tested for their potential cross-reactivity against human TAGLN in WB (Figure 11a) and in ELISA (Figure 11b) and against bacterial OMPs (both OmpK36 and OmpF) in ELISA (Figure 11c). While all commercial monoclonal antibodies recognized TAGLN and purified OmpK36 and OmpF in ELISA (although apparently with distinct efficiencies), three of them, M03, M04 and M06, recognized TAGLN also in WB further con confirming the existence of a cross-mimicry between human TAGLN and the bacterial OMPs.
Discussion
In a previous work [7] we demonstrated that in human coronary atherosclerotic plaques an antigen-driven B-cell evolution takes place, indicating the local presence of an antigen that stimulates the immune system. We now show that in human coronary atherosclerotic plaques B-cells are indeed engaged by local antigens and produce antibodies clones able to cross-react both with the fibrocyte cytoskeleton protein transgelin and with antigenic determinants of the outer membrane proteins of gram-negative pathogens belonging to the enterobacteriacee family. This original observation unequivocally demonstrate the reason for the recruitment of a population of B cells in human plaques. Although our observation lacks the formal demonstration of a direct pathogenetic or a protective role of this process, the molecular characterization of immunological targets is crucial for the understanding of a complex disease in witch the adaptive immune response plays an important role in all its phases of development [2]. Moreover, several previous observations could be re-analyzed in light of this observation. Indeed this finding could also explain why, despite some retrospective and cross-sectional sero-epidemiological studies found a strong association between distinct bacterial infections and coronary artery disease [12], [15], [17], [18], [27], [28], [29], specific pathogens where rarely detected in the arterial vessel walls. Indeed, this work opens the possibility of considering in the aetiopathology of the atherosclerotic disease a “hit-and-run” mechanism, in which the antigenic stimulations due to a self antigen or to the intermittent circulation of bacterial particles may persist, even in absence of a local replication [12], [30], [31]. It can be speculated that in atherosclerotic plaques both acute infections or even the mere spreading of gram- bacterial antigens, even from distant sites, may trigger rapid inflammatory changes and specific T- and B-cell responses within days or weeks [11], [14], [15] in spite of the local absence of the microbe itself, thus influencing the status of the local disease. In this model, a role in the progression of the atherosclerotic disease can also be played by low density lipoprotein (LDL) microparticles or outer membrane vesicles that can vehicle bacterial OMPs from the circulation to the site of atherosclerotic plaque growth [32], [33]. In this view our work can also explain why periodontitis, characterized by transient bacteraemia originated from the oral lesion, seems to be a risk factor for cardiovascular disease [34]; or why infections of the upper respiratory and urinary tracts due to gram-negative bacteria belonging to the enterobacteriaceae family represent, especially in the elderly and for diabetic patients, a risk factor for AMI or stroke [2], [11], [14], [15]. Antigenic mimicry between microbial and self structures has already been described [16], [22], [31] but our work provides for the first time a molecular dissection and characterization of this still elusive phenomenon, showing that within the plaques self- (TAGLN) and exogenous- (OMPs) antigens are recognized by highly mutated class-switched antibodies.
The nature of the two antigens recognized by the antibodies locally produced in the atherosclerotic plaque requires some additional considerations. OmpK36 (and possibly other OMPs) was demonstrated to activate immune cells via Toll-like receptors as well as antigen-presenting cells including B cells, gaining access to the major histocompatibility complex class I pathway and triggering the initiation of cytotoxic responses even in the absence of CD4+ T-cells help [35], [36]. On the other hand TAGLN has already been demonstrated to play a role in atherosclerosis. It was shown that in ApoE-deficient mice the ablation of TAGLN, increases the plaque area by enhancing the SMC phenotypic shift from contractile to synthetic/proliferative [37], [38]. Furthermore, disruption of TAGLN promotes arterial inflammation in mice through reactive oxygen species (ROS)-mediated NF-κB pathways [37], [39], increases atherosclerotic lesion area and favours SMC transdifferentiation into foam cell [37]. However, in human carotid plaques, most of the TAGLN+ cells were not recognized by cross-reactive antibodies produced in coronary plaques, as Fab7816. This may suggest that epitope accessibility in these cells, or specific antigenic modifications or intracellular processing occur in this cell population that are necessary for auto-antibody binding in human lesions. This cell population has the molecular feature of a subpopulation of monocyte-derived cells named fibrocytes. This cells have been previously identified in the fibrous caps of human atheromas and in several animal models of peripheral vascular disease. Although these cell type share molecular markers of either macrophages or fibroblasts, they remain relatively undifferentiated and express CD45 (also observed in our plaque samples) [40]. As suggested by animal models, fibrocytes might contribute to the pathogenesis of ischemic cardiomyopathy and might have a protective or reparative effect in the setting of uncontrolled or persistent in vivo TH1 cell cytokine exposure, whereas in response to persistent TH2 cell cytokine exposure (as during B-cell stimulation) they become profibrotic [24]. Whether locally produced cross-reacting IgGs play a specific role in any of these events, is still to be elucidated. Noteworthy, only a number of the atherosclerotic carotid samples were Fab7816+, thus suggesting that this mechanism might specifically identify a distinct plaque phenotype. Further studies are required to establish a relationship between Fab7816 staining and plaque features or clinical characteristics, in order to stratify patients.
However, the demonstration that, in atherosclerotic plaques of ACS patients, antibodies that cross-react with a bacterial antigen and with a self protein involved in atherogenesis together with the fact that these antibodies seem to recognize TAGLN in lesions from a number of unrelated patients opens new perspectives in understanding the role played by the adaptive immune system in the pathogenesis of the atherosclerotic inflammatory processes, providing a scientific ground to several clinical and pathological features of the disease. In theory, the continuous and transient exposure to exogenous cross-reacting molecules during asymptomatic bacteraemia events can guarantee the surviving stimuli to the self-reactive immune cells within the lesions [6]. Moreover, self antigens produced by dying cells or neo-epitopes generated by LDL oxidation (oxLDL) together with the development of autoantibodies against oxLDL have been recently suggested as pro-atherogenic events [2], [41]. A similar mechanism involving cross-reactivity between commensal microbiota and self structures was also recently demonstrated to play pathogenetic role in mice models of autoimmune demyelination [22].
Unfortunately, formal demonstration of the aetiopatological role of the molecular mimicry we describe may not be reliably reproduced in animals, due to the difficulty of reproducing human autoimmune diseases in experimental models. Current animal models of atherosclerosis do not fully mimic human disease (with particular regard to coronary atherosclerosis and AMI) and the immune response eventually generated by vaccination would not necessarily reflect the role of the local immune response present within the lesions.
As a conclusion, the availability of these data could be central for planning new strategies to correctly address the role of immune response in coronary atherosclerosis. The identification of exogenous and endogenous triggers may help to identify new therapies, such as inducing local B-cell local apoptosis or depletion by targeting B-cell receptor signalling with the identified antigens or synthetic mimotopes; or driving B or T-cell function towards a regulatory phenotype to inhibit the inflammatory cascade [1]. The immunization strategies with specific exogenous antigens may prevent bacterial immunogens from reaching atherosclerotic lesions. Moreover, a more precise identification of the nature of the epitopes involved in this complex process has the potential of allowing the design of novel diagnostic assays that may be able to predict the disease status in atherosclerotic patients and to help to define the risk for disease progression.
Methods
Ethics Statement
The San Raffaele ethics committee approved the study and all patients gave their written informed consent to participate.
Samples Collection and Amplification of Heavy and Light Chain Genes
Four coronary atherosclerotic plaques (ID-A, ID-B, ID-C, ID-D) were collected and stored in liquid nitrogen from four male patients with ACS (Table S1), undergoing coronary atherectomy. None of the patients had autoimmune or systemic diseases or diabetes, nor had they undergone recent surgery or suffered for from recent infectious diseases. Plaques were homogenized and total mRNA was extracted using RNeasy Micro kit (Qiagen) according to the manufacturer’s instructions. Amplification of heavy and light chain genes was performed as previously described [7].
Molecular Cloning and Combinatorial Antibody Fab Fragment Phage-display Libraries
The PCR products of heavy and light chains amplified from human coronary plaques were cloned into a phagemidic vector (pRB32) that allowed the generation of combinatorial antibody Fab fragment phage-display libraries [7], [42], [43].
Lysates Preparation from Atherosclerotic Carotid Samples and from Bacterial Pathogens
Human atherosclerotic carotid artery biopsies from patients submitted to endoarterectomy were collected in lysis buffer (RIPA buffer), homogenized with Tissue Ruptor (Qiagen) and centrifuged at 13,000 rpm for 30 min at 15°C. Supernatant protein content was evaluated by BCA (Pierce). To prepare bacterial lysates, Staphylococcus aureus, Proteus mirabilis, Klebsiella pneumoniae, Enterococcus cloacae, Streptococcus pyogenes, Neisseriae gonhorreae, Listeria monocytogenes, Haemophilus influenzae were inoculated in 10 mL of super broth or seeded on blood agar, if required, and grown at 37°C overnight. Cultures were harvested by centrifugation and resuspended in RIPA buffer containing a protease inhibitor (phenylmethylsulfonyl fluoride (PMSF). After a sonication step the lysate was cleared by centrifugation and stored at −20°C until usage.
Immunoaffinity Selection by Biopanning on Atherosclerotic Carotid Lysate
The night before biopanning, the ELISA plate was coated O/N at 4°C with the carotid lysate (100 ng/well) solution in a coating buffer (PBS, pH = 7.4). After blocking with 3% bovine serum albumine (BSA) in phosphate buffer solution (PBS), for 1 h, 37°C, 70 µL of phage suspension, (about 1011 PFU), were added to each well and incubated for at least 2 hrs at 37°C. Selected phages were recovered and used to infect a fresh E. coli XL-1Blue culture. Biopanning was then conducted as previously described [25] for four rounds, allowing enrichment of the selected population.
Production and Purification of Fabs
E. coli XL-1Blue was used for the expression of soluble Fabs as previously described [25].
Production and Purification of Klebsiella pneumoniae OmpK36 and Proteus mirabilis OmpF
OmpK36, and OmpF were amplified from Klebsiella pneumoniae and Proteus mirabilis lysates respectively and cloned into a pET-28b expression vector (Novagen) by using the following primer pairs containing two distinct 5′ restriction endonuclease sequences: OmpK36NcoIFW: GCGCTAGTATGccatgggcATGAAAGTTAAAGTACTGT and OmpK36XhoIRW: GCGCTTCCTCGATACCTCGAGCTAGAACTGGTAAA; OmpK36BamHIFW: GCGCTAGTCTGggatccgATGAAAGTTAAAGTACTGTC and OmpK36XhoIRW: TTCCTCGATACCTCGAGCTAGAACTGGTAAACCAG; OmpF-Pr-BamHI TGATCGATCGAAATGggatccgATGATGAAGCGCAATAT and OmpF-Pr-XhoI GTA CCT AAT CCAGCAACGctcgagGAACTGATAAGT. For the amplifications the following thermal profile was used: 95°C for 5 min; 95°C for 30 sec., 55°C for 30 sec. and 72°C for 1.5 min. for 30 cycles; 72°C for 10 min. The amplification products and the pET28b vectors were double digested for 4 hours with the following couples of restriction endonucleases: NcoI/XhoI (New England Biolabs) or BamHI/XhoI (New England Biolabs) for OmpK36 and only BamHI/XhoI for OmpF, loaded onto a 1% agarose gel and purified by using Qiagen Gel Extraction kit. The corresponding digested amplicons were overnight ligated by using 10 units of T4 ligase (Roche). After transformation of bacterial cells (E. coli XL1-Blue) and plating, individual colonies were inoculated on Luria Broth (LB) and grown overnight. After plasmid purification (Qiagen Miniprep kit) the inserts were sequenced with the following primers: T7FWpET: TAATACGACTCACTATAGGG and T7termpET: GCTAGTTATTGCTCAGCGG. OMP Expression was performed following manufacturer instructions (pET System Manual - Novagen), using a final IPTG concentration of 1 mM to induce the expression of OMPs. After induction, cultures were chilled on ice and 20 µL of induced culture and 20 µL of non-induced control culture were boiled with SDS loading buffer at 95°C for 5 min. and then loaded in SDS-PAGE. Ni-NTA purification was performed following manufacturer instructions (QiaExpressionist - Qiagen) and using E. coli BL21(DE3) bacterial cells and NI-NTA resin. Briefly, after IPTG induction of protein expression and culture centrifugation, bacterial cells were resuspended with Denaturing Binding Buffer (Insoluble Fraction – IF) and filter sterilized. Two mL of Ni-NTA resin was added to IF and left in agitation overnight at R.T. and then the resin was packed in one empty column. The resin was washed with 50 volumes (100 mL) of Denaturing Washing Buffer and the bound fraction was eluted twice with 2 mL of Denaturing Elution Buffer (dEB) pH = 5.9 and other 7 times with dEB pH = 4.5. All fractions were immediately neutralized to pH 7.4. The eluted fractions were loaded on SDS-PAGE to estimate the purity of recombinant OmpK36.
ELISA with Fabs and Purified OMPs
Eight µg of each OMP were coated on a 96 well ELISA plate in PBS, pH = 5.0 overnight at 4°C. The following day, the plate was blocked with PBS/BSA1%, and purified Fabs or freeze-and-thaw preparations were added (about 8 µg/ml) to each well. After washing with PBS/0.1% Tween-20, the anti-Human-Fab antibody-HRP (SIGMA-Aldrich), was added and incubated for 45–60 min at 37°C. After washing with PBS/0.1% Tween-20, 40 µL of TMB solution (Pierce) was added and the plate read at 450 nm.
Western Blot on Induced/Non-Induced E. coli BL21(DE3) Total Lysates with Purified Fabs
Western Blot (WB) was performed on total bacteria proteins from IPTG induced or non-induced cultures or on purified OmpK36 or OmpF proteins. Protein concentration was determined by BCA kit (Pierce), following manufacturer instructions. Five hundred ng of purified protein or 20 µL of total cell lysate was loaded in each well. Proteins were transferred to PVDF membrane at 0.350 A for 2 hours, then the membrane was blocked with PBS/10% BSA at 4°C in agitation overnight. The day after the membrane was incubated with Fab7816 (10 µg/mL) diluted in PBS/BSA5% for 1 hour at R.T. and then washed 3 times with PBS/0.1% Tween-20. The membrane was incubated for 1 hour at R.T. with HRP-conjugated anti-Human Light Chain K antibody (Pirce) and developed by SuperSignal West Pico Chemiluminescent Substrate (Pierce), following manufacturer instructions. WB was also developed with anti-HIS-HRP antibody (Roche) to verify the presence of HIS-tag at N-term of OmpK36.
Bidimensional Electrophoresis (2DE) and Mass Spectrometry on Carotid Plaque Lysates
A carotid plaque fragment was weighted (65 mg), cut in small fragments and directly smashed with a Dounce in 500 µL of R5 buffer, containing: 8 M urea, 2M thiourea, 4% CHAPS, 0.05% Zwittergent, 40 mM Trizma base and a cocktail of protease inhibitors. The lysate was then sonicated for 5 min and centrifuged at 13,000 rpm for 30 min at 15°C. Supernatant protein content was evaluated by BCA (Pierce). The proteins (200 µg) were dissolved in R5 buffer (final volume 130 µL), and then added to DeStreak (100 mM) and 2% IPG buffer pH 3-10NL, prior to loading the sample on 7 cm strip pH 3-10NL. Total focusing run for the 1st dimension was 50,000 Vh The 2nd dimension was performed using 12.5% acrylamide SDS-PAGE.
For the 2D electrophoresis Western Blotting (2DE-WB), the proteins (70 µg) dissolved in R5 buffer (final volume 130 µl), were added of DeStreak (100 mM) and 2% IPG buffer pH 3-10NL, prior to loading the sample on strip pH 3-10NL, 7 cm. After 2D electrophoresis proteins were then transferred to PVDF membrane by semi-dry electroblotting and probed with Fab 7816-FLAG. Immune complexes were visualized by incubation with HRP-conjugated anti-FLAG antibody (Sigma-Aldrich) and chemiluminescent detection.
Protein spots of interest were excised from the gel and digested with trypsin and directly analysed by MALDI-ToF mass spectrometry, using alpha-cyano-4-hydroxycinnamic acid (Sigma-Aldrich) as matrix. Mascot software (Matrix Science) was used for protein searching in IPI_human_20100623 database. Identification was accepted when the Mascot score was >66, with a good sequence coverage.
Western Blot with Preparation of Purified Human TAGLN
The binding of representative Fabs248, Fab172, Fab1630 and Fab7816 to TAGLN was performed using 400 ng of purified TAGLN (Origene, TP302448) Myc-tagged loaded in each lane. TAGLN was run in SDS-PAGE and then transferred on PVDF membrane for 2 h at 0.350 A. PVDF was then blocked with PBS/10% BSA or PBS/10% Milk O/N at 4°C in agitation. Anti-Myc-Peroxidase (Abcam, ab62928 in PBS/BSA5%) and anti-human TAGLN (Abnova, H00006876-M01 in PBS/5% Milk) commercial antibodies were used as positive controls. Purified Fabs were used in the assay. Anti-Light Chain K-Peroxidase antibody (PSB/5% BSA) and anti-Mouse-Fab antibody (PBS/Milk 5%) were used to reveal Fab binding or commercial anti-TAGLN binding respectively. After extensive washing with PBS/Tween-20 0.1% WB was developed with SuperSignal West Pico Chemiluminescent Substrate (Pierce).
Histology, Immunohistochemistry and Immunofluorescence on Plaque Sections
Histology and immunofluorescence/immunohistochemistry were performexd on two coronary plaques and 31 carotid plaques harvested during endoarterectomy immediately after excision. Specimens were fixed in 4% paraformaldehyde in PBS. Carotid plaques were cut in consecutive 2 mm thick rings, decalcified in Osteodec (BioOptica) when required. All biopsies were cryoprotected in 10% sucrose in PBS, embedded in killik (BioOptica), snap frozen in isopentane/liquid nitrogen and stored at −80°C. Cryosections (5 µm thick) were obtained from every ring/sample by Leica CM1850 cryostat (Leica Microsystems GmbH) and stained either with Hematoxylin/Eosin or Movat’s pentachrome. The morphology was examined in 4 sections/ring by light microscope Eclipse 55i equipped with DS-L1 camera, and multiple images were composed by LUCIA 4.82 software (Nikon) to reconstruct the section. Carotid plaques were classified as stable, vulnerable or unstable, following Virmani’s modified AHA classification [44]. Serial sections (10 µm thick) representative of the lesion or without atheroma were selected for each specimen and submitted to immunolabeling. To avoid unspecific reactivity with immune complexes or endogenous human IgG in human atherosclerotic lesions, Fab7816 was tagged with a recombinant artificial FLAG tag, as previously described [45]. Different combinations of antibodies were tested in single or multiple labelling. The following antibodies were used: Fab7816-FLAG (100 ng/mL, overnight, 4°C) detected either with anti-FLAG-FITC (diluted 1∶100 1 h R.T., clone M2, Sigma-Aldrich), or mouse-anti-FLAG–HRP (diluted 1∶100 1 h R.T., clone M2, Sigma-Aldrich) revealed by DAB detection kit (Vector Laboratories Inc); mouse-anti-TAGLN (clone H00006876-M01) and goat anti- human TAGLN polyclonal antibody (diluted 1∶200 and 1∶100 respectively, overnight 4°C, both from Abnova Corporation) revealed either by goat-anti-mouse IgG(H+L) AlexaFluor594 or goat-anti-mouse IgG2a AlexaFluor488, or donkey-anti-goat IgG AlexaFluor488, or donkey-anti-goat IgGAlexaFluor680 (diluted 1∶500 45 min RT, all from Molecular Probes Invitrogen); mouse-anti-human CD68 (diluted 1∶100 2 h RT, clone KP-1, DAKO) revealed by goat-anti-mouse IgG1k AlexaFluor 488 or goat-anti-mouse IgG(H+L) AlexaFluor594; mouse-anti-human Collagen type I (diluted 1∶100, overnight at 4°C, Calbiochem Merck, Darmstadt, Germany) revealed by goat-anti-mouse IgG AlexaFluor680 or goat-anti-mouse IgG AlexaFluor488; mouse-anti-human CD45-PE (diluted 1∶100, 1 h RT, BD Biosciences, Franklin Lakes, NJ USA). Unrelated E8Fab-FLAG [25], [45] or omission of the primary antibodies served as negative controls. Single staining was performed in parallel to double or multiple as positive controls. DAPI (Sigma-Aldrich) or Mayer’s Haematoxylin opportunely counterstained the nuclei. Sections were examined under Nikon Eclipse 55i microscope or under Leica TCS SP5 confocal microscope (Leica Microsystems). Two scientists evaluated the sections independently, and transmitted light and fluorescence images were obtained. Confocal 2D free projection max from Z-series of images were acquired in single or double channel, respectively, then superposed by Leica LAS AF software and mounted in panels by AdobePhotoshop CS.
Generation of fibrocytes in vitro. Buffy Coats from healthy donors were collected as previously described [46] and peripheral blood mononuclear cells (PBMCs) were isolated by density-gradient centrifugation using Histopaque-1077) according to the manufacturer’s instructions. CD14+ monocytes were isolated by positive selection with magnetic MicrobBeads (Miltenyi Biotec, Bisley, UK). Fibrocytes were generated by culture in serum-free growth medium (SFM, RPMI 1640, Life Technologies, supplemented with 40 U/mL penicillin and 0.4 mg/mL streptomycin, 1%HEPES, 1% liquid media supplement ITS+3, 1% non-essential amino acids, 1% Sodium Pyruvate). CD14+ cells (2,5×105/mL) were resuspended in SFM and cultured on 13mm diameter round glass coverslips into 24-well plastic plates in a humidified incubator at 37°C, 5% CO2 for 4 days. MRC-5 cells (human fetal lung fibroblasts, CCL-171™, ATCC) at passage 25 were similarly seeded at density of 2,5×105/mL in MEM, Life Technologies, supplemented with 10% FBS and 40 U/mL penicillin and 0.4 mg/mL streptomycin to serve as controls. Reagents were provided by SIGMA-Aldrich, Steinheim, Germany whereas not indicated.
Immunofluorescence on Fibrocytes
CD14+ fibrocytes and MRC-5 cells freshly-fixed in 2% paraformaldehyde in PBS were rinsed in PBS, permeabilized in 0.1% TritonX100 in PBS, then submitted to immunofluorescence against 7816FabFLAG, E8FabFLAG, CD45, CD68, Collagen Type I and TAGLN similarly to plaque sections. Specimens were analyzed at confocal microscope as described above.
Supporting Information
Acknowledgments
We are grateful to Annapaola Landolfo for proteomic assistance, to Roberto Ferrarese and Alessandra Franchino for skilful technical assistance, to Federico Maisano, Zaverio Ruggiero and Luca Guidotti for helpful discussions and to Enrico M. Marone for carotid sample collection. Diego Saita conducted this study as partial fulfillment of his PhD in Molecular Medicine, Program in Preventive and Predictive Medicine, San Raffaele University, Milan, Italy.
Funding Statement
This work was partially supported by a grant from Bracco Imaging SpA, and by the Young Investigators Grant GR08-41 of the Italian Ministry of Health. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
References
- 1. Lahoute C, Herbin O, Mallat Z, Tedgui A (2011) Adaptive immunity in atherosclerosis: mechanisms and future therapeutic targets. Nat Rev Cardiol 8: 348–358. [DOI] [PubMed] [Google Scholar]
- 2. Hansson GK, Hermansson A (2011) The immune system in atherosclerosis. Nat Immunol 12: 204–212. [DOI] [PubMed] [Google Scholar]
- 3. Grabner R, Lotzer K, Dopping S, Hildner M, Radke D, et al. (2009) Lymphotoxin beta receptor signaling promotes tertiary lymphoid organogenesis in the aorta adventitia of aged ApoE−/− mice. J Exp Med 206: 233–248. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4. Houtkamp MA, de Boer OJ, van der Loos CM, van der Wal AC, Becker AE (2001) Adventitial infiltrates associated with advanced atherosclerotic plaques: structural organization suggests generation of local humoral immune responses. J Pathol 193: 263–269. [DOI] [PubMed] [Google Scholar]
- 5. Watanabe M, Sangawa A, Sasaki Y, Yamashita M, Tanaka-Shintani M, et al. (2007) Distribution of inflammatory cells in adventitia changed with advancing atherosclerosis of human coronary artery. J Atheroscler Thromb 14: 325–331. [DOI] [PubMed] [Google Scholar]
- 6. Aloisi F, Pujol-Borrell R (2006) Lymphoid neogenesis in chronic inflammatory diseases. Nat Rev Immunol 6: 205–217. [DOI] [PubMed] [Google Scholar]
- 7. Burioni R, Canducci F, Saita D, Perotti M, Mancini N, et al. (2009) Antigen-driven evolution of B lymphocytes in coronary atherosclerotic plaques. J Immunol 183: 2537–2544. [DOI] [PubMed] [Google Scholar]
- 8. De Palma R, Del Galdo F, Abbate G, Chiariello M, Calabro R, et al. (2006) Patients with acute coronary syndrome show oligoclonal T-cell recruitment within unstable plaque: evidence for a local, intracoronary immunologic mechanism. Circulation 113: 640–646. [DOI] [PubMed] [Google Scholar]
- 9. Weber C, Noels H (2011) Atherosclerosis: current pathogenesis and therapeutic options. Nat Med 17: 1410–1422. [DOI] [PubMed] [Google Scholar]
- 10. Angiolillo DJ, Liuzzo G, Pelliccioni S, De Candia E, Landolfi R, et al. (2003) Combined role of the Lewis antigenic system, Chlamydia pneumoniae, and C-reactive protein in unstable angina. J Am Coll Cardiol 41: 546–550. [DOI] [PubMed] [Google Scholar]
- 11. Clayton TC, Thompson M, Meade TW (2008) Recent respiratory infection and risk of cardiovascular disease: case-control study through a general practice database. Eur Heart J 29: 96–103. [DOI] [PubMed] [Google Scholar]
- 12. Stassen FR, Vainas T, Bruggeman CA (2008) Infection and atherosclerosis. An alternative view on an outdated hypothesis. Pharmacol Rep 60: 85–92. [PubMed] [Google Scholar]
- 13. Ruggeri ZM (2002) Platelets in atherothrombosis. Nat Med 8: 1227–1234. [DOI] [PubMed] [Google Scholar]
- 14. Grau AJ, Urbanek C, Palm F (2010) Common infections and the risk of stroke. Nat Rev Neurol 6: 681–694. [DOI] [PubMed] [Google Scholar]
- 15. Smeeth L, Thomas SL, Hall AJ, Hubbard R, Farrington P, et al. (2004) Risk of myocardial infarction and stroke after acute infection or vaccination. N Engl J Med 351: 2611–2618. [DOI] [PubMed] [Google Scholar]
- 16. Ford PJ, Gemmell E, Chan A, Carter CL, Walker PJ, et al. (2006) Inflammation, heat shock proteins and periodontal pathogens in atherosclerosis: an immunohistologic study. Oral Microbiol Immunol 21: 206–211. [DOI] [PubMed] [Google Scholar]
- 17. Koren O, Spor A, Felin J, Fak F, Stombaugh J, et al. (2010) Human oral, gut, and plaque microbiota in patients with atherosclerosis. Proc Natl Acad Sci U S A 108 Suppl 14592–4598. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18. Kozarov EV, Dorn BR, Shelburne CE, Dunn WA Jr, Progulske-Fox A (2005) Human atherosclerotic plaque contains viable invasive Actinobacillus actinomycetemcomitans and Porphyromonas gingivalis. Arterioscler Thromb Vasc Biol 25: e17–18. [DOI] [PubMed] [Google Scholar]
- 19. Blankenberg S, Rupprecht HJ, Bickel C, Espinola-Klein C, Rippin G, et al. (2001) Cytomegalovirus infection with interleukin-6 response predicts cardiac mortality in patients with coronary artery disease. Circulation 103: 2915–2921. [DOI] [PubMed] [Google Scholar]
- 20. Knip M, Virtanen SM, Seppa K, Ilonen J, Savilahti E, et al. (2010) Dietary intervention in infancy and later signs of beta-cell autoimmunity. N Engl J Med 363: 1900–1908. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21. Vaahtovuo J, Munukka E, Korkeamaki M, Luukkainen R, Toivanen P (2008) Fecal microbiota in early rheumatoid arthritis. J Rheumatol 35: 1500–1505. [PubMed] [Google Scholar]
- 22. Berer K, Mues M, Koutrolos M, Rasbi ZA, Boziki M, et al. (2011) Commensal microbiota and myelin autoantigen cooperate to trigger autoimmune demyelination. Nature 479: 538–541. [DOI] [PubMed] [Google Scholar]
- 23. Camoretti-Mercado B, Forsythe SM, LeBeau MM, Espinosa R 3rd, Vieira JE, et al (1998) Expression and cytogenetic localization of the human SM22 gene (TAGLN). Genomics 49: 452–457. [DOI] [PubMed] [Google Scholar]
- 24. Reilkoff RA, Bucala R, Herzog EL (2011) Fibrocytes: emerging effector cells in chronic inflammation. Nat Rev Immunol 11: 427–435. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25. Burioni R, Plaisant P, Manzin A, Rosa D, Delli Carri V, et al. (1998) Dissection of human humoral immune response against hepatitis C virus E2 glycoprotein by repertoire cloning and generation of recombinant Fab fragments. Hepatology 28: 810–814. [DOI] [PubMed] [Google Scholar]
- 26. Stow NW, Douglas R, Tantilipikorn P, Lacroix JS (2010) Superantigens. Otolaryngol Clin North Am 43: 489–502, vii. [DOI] [PubMed] [Google Scholar]
- 27. Espinola-Klein C, Rupprecht HJ, Bickel C, Lackner K, Schnabel R, et al. (2007) Inflammation, atherosclerotic burden and cardiovascular prognosis. Atherosclerosis 195: e126–134. [DOI] [PubMed] [Google Scholar]
- 28. Liuzzo G, Baisucci LM, Gallimore JR, Caligiuri G, Buffon A, et al. (1999) Enhanced inflammatory response in patients with preinfarction unstable angina. J Am Coll Cardiol 34: 1696–1703. [DOI] [PubMed] [Google Scholar]
- 29. Rupprecht HJ, Blankenberg S, Bickel C, Rippin G, Hafner G, et al. (2001) Impact of viral and bacterial infectious burden on long-term prognosis in patients with coronary artery disease. Circulation 104: 25–31. [DOI] [PubMed] [Google Scholar]
- 30. Honda T, Oda T, Yoshie H, Yamazaki K (2005) Effects of Porphyromonas gingivalis antigens and proinflammatory cytokines on human coronary artery endothelial cells. Oral Microbiol Immunol 20: 82–88. [DOI] [PubMed] [Google Scholar]
- 31. Mandal K, Jahangiri M, Xu Q (2005) Autoimmune mechanisms of atherosclerosis. Handb Exp Pharmacol. 723–743. [DOI] [PubMed] [Google Scholar]
- 32. Rao J, DiGiandomenico A, Unger J, Bao Y, Polanowska-Grabowska RK, et al. (2008) A novel oxidized low-density lipoprotein-binding protein from Pseudomonas aeruginosa. Microbiology 154: 654–665. [DOI] [PubMed] [Google Scholar]
- 33. Bomberger JM, Maceachran DP, Coutermarsh BA, Ye S, O’Toole GA, et al. (2009) Long-distance delivery of bacterial virulence factors by Pseudomonas aeruginosa outer membrane vesicles. PLoS Pathog 5: e1000382. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34. Paju S, Sinisalo J, Pussinen PJ, Valtonen V, Nieminen MS (2007) Is periodontal infection behind the failure of antibiotics to prevent coronary events? Atherosclerosis 193: 193–195. [DOI] [PubMed] [Google Scholar]
- 35. Jeannin P, Bottazzi B, Sironi M, Doni A, Rusnati M, et al. (2005) Complexity and complementarity of outer membrane protein A recognition by cellular and humoral innate immunity receptors. Immunity 22: 551–560. [DOI] [PubMed] [Google Scholar]
- 36. Vidakovics ML, Jendholm J, Morgelin M, Mansson A, Larsson C, et al. (2010) B cell activation by outer membrane vesicles–a novel virulence mechanism. PLoS Pathog 6: e1000724. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37. Feil S, Hofmann F, Feil R (2004) SM22alpha modulates vascular smooth muscle cell phenotype during atherogenesis. Circ Res 94: 863–865. [DOI] [PubMed] [Google Scholar]
- 38. Doran AC, Meller N, McNamara CA (2008) Role of smooth muscle cells in the initiation and early progression of atherosclerosis. Arterioscler Thromb Vasc Biol 28: 812–819. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39. Shen J, Yang M, Ju D, Jiang H, Zheng JP, et al. (2010) Disruption of SM22 promotes inflammation after artery injury via nuclear factor kappaB activation. Circ Res 106: 1351–1362. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40. Iwata H, Manabe I, Fujiu K, Yamamoto T, Takeda N, et al. (2010) Bone marrow-derived cells contribute to vascular inflammation but do not differentiate into smooth muscle cell lineages. Circulation 122: 2048–2057. [DOI] [PubMed] [Google Scholar]
- 41. Binder CJ (2010) Natural IgM antibodies against oxidation-specific epitopes. J Clin Immunol 30 Suppl 1S56–60. [DOI] [PubMed] [Google Scholar]
- 42. Barbas CF 3rd, Kang AS, Lerner RA, Benkovic SJ (1991) Assembly of combinatorial antibody libraries on phage surfaces: the gene III site. Proc Natl Acad Sci U S A 88: 7978–7982. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43. Burioni R, Plaisant P, Bugli F, Delli Carri V, Clementi M, et al. (1998) A vector for the expression of recombinant monoclonal Fab fragments in bacteria. J Immunol Methods 217: 195–199. [DOI] [PubMed] [Google Scholar]
- 44. Virmani R, Kolodgie FD, Burke AP, Farb A, Schwartz SM (2000) Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler Thromb Vasc Biol 20: 1262–1275. [DOI] [PubMed] [Google Scholar]
- 45. Burioni R, Canducci F, Mancini N, Clementi N, Sassi M, et al. (2010) Monoclonal antibodies isolated from human B cells neutralize a broad range of H1 subtype influenza A viruses including swine-origin Influenza virus (S-OIV). Virology 399: 144–52. [DOI] [PubMed] [Google Scholar]
- 46. Curnow SJ, Fairclough M, Schmutz C, Kissane S, Denniston AK, et al. (2010) Distinct types of fibrocyte can differentiate from mononuclear cells in the presence and absence of serum. PLoS One 5: e9730. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.